This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 1998 May;50(5):1211-2.

doi: 10.1212/wnl.50.5.1211.

New lessons from old drugs: amantadine and Parkinson's disease

PMID: 9595964
DOI: 10.1212/wnl.50.5.1211

Clinical Trial

New lessons from old drugs: amantadine and Parkinson's disease

C G Goetz. Neurology. 1998 May.

. 1998 May;50(5):1211-2.

doi: 10.1212/wnl.50.5.1211.

Author

PMID: 9595964
DOI: 10.1212/wnl.50.5.1211

No abstract available

PubMed Disclaimer

Comment in

More recent lessons from amantadine.
Uitti RJ. Uitti RJ. Neurology. 1999 Feb;52(3):676. doi: 10.1212/wnl.52.3.673-c. Neurology. 1999. PMID: 10025822 No abstract available.

Comment on

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Verhagen Metman L, et al. Neurology. 1998 May;50(5):1323-6. doi: 10.1212/wnl.50.5.1323. Neurology. 1998. PMID: 9595981 Clinical Trial.
Acute delirium after withdrawal of amantadine in Parkinson's disease.
Factor SA, Molho ES, Brown DL. Factor SA, et al. Neurology. 1998 May;50(5):1456-8. doi: 10.1212/wnl.50.5.1456. Neurology. 1998. PMID: 9596005

Similar articles

Amantadine in advanced Parkinson's disease: good use of an old drug.
Adler CH, Stern MB, Vernon G, Hurtig HI. Adler CH, et al. J Neurol. 1997 May;244(5):336-7. doi: 10.1007/s004150050098. J Neurol. 1997. PMID: 9178162 No abstract available.
[Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].
Dzudza M, Dzudza D. Dzudza M, et al. Med Arh. 1974 Jul-Aug;28(4):407-15. Med Arh. 1974. PMID: 4613968 Clinical Trial. Serbian. No abstract available.
Amantadine and other antiglutamate agents: management of Parkinson's disease.
[No authors listed] [No authors listed] Mov Disord. 2002;17 Suppl 4:S13-22. doi: 10.1002/mds.5557. Mov Disord. 2002. PMID: 12211136 Review. No abstract available.
Drugs for Parkinson's disease.
[No authors listed] [No authors listed] Lancet. 1978 Apr 8;1(8067):754-5. Lancet. 1978. PMID: 76754 No abstract available.
[Treatment of Parkinson disease in patients with surgical problems].
Sobolewski P. Sobolewski P. Neurol Neurochir Pol. 2003;37 Suppl 5:183-8. Neurol Neurochir Pol. 2003. PMID: 15098345 Review. Polish.

See all similar articles

Cited by

Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
Perez-Lloret S, Rascol O. Perez-Lloret S, et al. J Neural Transm (Vienna). 2018 Aug;125(8):1237-1250. doi: 10.1007/s00702-018-1869-1. Epub 2018 Mar 7. J Neural Transm (Vienna). 2018. PMID: 29511826 Review.
Assessment of therapeutic potential of amantadine in methamphetamine induced neurotoxicity.
Thrash-Williams B, Ahuja M, Karuppagounder SS, Uthayathas S, Suppiramaniam V, Dhanasekaran M. Thrash-Williams B, et al. Neurochem Res. 2013 Oct;38(10):2084-94. doi: 10.1007/s11064-013-1117-x. Epub 2013 Aug 6. Neurochem Res. 2013. PMID: 23918203
Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials.
Pawlak CR, Chen FS, Wu FY, Ho YJ. Pawlak CR, et al. Kaohsiung J Med Sci. 2012 Aug;28(8):407-17. doi: 10.1016/j.kjms.2012.02.010. Epub 2012 Apr 22. Kaohsiung J Med Sci. 2012. PMID: 22892161 Free PMC article. Review.

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information